CEP-701

Sex: Female, Male

Region of Enrollment

Objective response = Complete Response, absence sign/symptoms of disease (without use of growth factors, hydroxyurea, anagrelide, or transfusions for > 1 month); Partial Response, absence of progressive disease (PD), and improvement in 2+ parameters (if abnormal): Absolute neutrophil count (ANC), hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts; Clinical Improvement, absence of PD, and improvement in 1 parameter: ANC, hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts). [International Working Group on Myelofibrosis Research and Treatment]

Number of Participants With Objective Response

Overall Study

Srdan Verstovsek M.D./Associate Professor

Leukemia

Myelofibrosis

The University of Texas M.D. Anderson Cancer Center

CEP-701 for PH-negative Myelofibrosis

Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis

M.D. Anderson Cancer Center

Cephalon

primary myelofibrosis

ananas comosus

primary myelofibrosis/ananas comosus

CEP-701 for PH-negative Myelofibrosis

Täydellisin lääketieteellinen tietokanta tieteen tukemana